C-Z5VJOncolife Therapeutics
stem cell biology, molecular therapies, cancer
modulating
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Z5VJ
C-Z5VJC-Z5VJstem cell biology, molecular therapies, cancer
0-100 chain-logic scale · 15 dimensions · scored on public evidence
#longevity #longevitymedicine #supplements | Katia Dowling | 14 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreemen
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
Healthcare Private Placement and M&A Transactions Review Week Ending May 25, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending May 25 … valuation at $45 million. TELUS Global Ventures, Bird Capital, LionBird, Fusion Fund, Qiming Venture Partners USA, Gaingels, Keren Maccabi, Frank Sica, and other undisclosed investors also participated in the round. The company is a developer of a software solution that enables organizations to perform federated learning and analytics across decentralized data sources without transferring sensitive data. Persist AI: The company raised $12 million of Series A venture funding i
Facebook Avasta asju, mis sulle meeldivad . Facebooki sisselogimine Meiliaadress või mobiilinumber Parool Logi sisse Kas unustasid parooli? Loo uus konto Eesti English (US) فارسی العربية Türkçe Deutsch Français (France) Veel keeli ... Registreeru Logi sisse Messenger Facebook Lite Video Meta Pay Meta pood Meta Quest Ray-Ban Meta Meta AI Instagram Lõimed Privaatsuspõhimõtted Privaatsuskeskus Teave Loo reklaam Loo leht Arendajad Tööpakkumised Küpsised Reklaamivalikud Tingimused Abi Kontaktide üleslaadimine ja mittekasutajad Meta © 2026
We’re excited to welcome Nicola Jones-Crossley as our new Ecosystem Development Manager (QLD) 🎉 Big things are happening across Queensland’s quantum landscape, and Nicola is here to help bring them… | Quantum Australia LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
Altogen Labs - Altogen Labs, a leading biology CRO, offers... Facebook Log In Altogen Labs's Post Altogen Labs April 23, 2025 · Shared with Public Altogen Labs, a leading biology CRO, offers the in-house validated A172 glioblastoma xenograft model for preclinical oncology studies. Derived from a human glioblastoma cell line with intact PTEN and wild-type p53, this model enables evaluation of therapies targeting the PI3K/AKT/mTOR pathway. Its reliable tumorigenicity in immunodeficient mice and relevance to non-EGFR-amplified glioma subtypes make it a valuable tool for anti-cancer drug deve
#035: July 6th, 2021 - Longevity Marketcap Telemetry Longevity Marketcap Newsletter Subscribe Sign in #035: July 6th, 2021 - Longevity Marketcap Telemetry On Deck Longevity Biotech. VitaDAO raise. Insilico Medicine, Continuum Biosciences, Vita Therapeutics. Mystery non-profit. Adventures in longevity. Nathan S. Cheng Jul 07, 2021 2 6 Share Announcements Last Week(s) in Longevity Longevity Futures Capital Raise Radar Longevity Jobs New Companies on Longevity List Adventures in Longevity My Links * Disclaimer : None of this should be taken as financial advice. It is for educational purposes only … nouncements I’ve joined On Deck as Program Director for their Longevity Biotech Fellowship . After working every day, night, and weekend straight, we launched the program last Tuesday. The launch was an incredible success thanks to the amazing Founding Fellows and speakers of the program, the On Deck team, my awesome program partner Ada Nguyen -- and this super epic tweetstorm by Balaji Srinivasan . Why: We need more people working on longevity, especially founders! So we are … ase the number of people working to build longevity biotech companies. Who: The fellowship program takes in people who want to DO something about the problem of aging: Founders, aspiring founders , operators looking to join a startup, or investors, regardless of whether you have the “right” background or not. (See Ben Kamens , Matt Scholz , Reason , etc for examples) What: ODLB is a continuous community program that runs year-long with workshops, deep dives with industry expe … mp; networking events, and some exciting in-person events post-COVID. When: The deadline for applications for the first cohort is August 31st . Applicants will be accepted on a rolling basis so applying earlier will increase your chances of securing a spot. The first cohort kicks off on September 12th. Cost: Academic pricing is available. Financing plans are available. There are scholarships from On Deck’s Access Fund, too. I will be funding several scholarships out of my own … ty to make a big impact on human longevity and age-related disease through this fellowship so I encourage anyone who wants to DO something about aging to apply . I’ve also started a fund: Healthspan Capital , which invests in early-stage longevity biotech companies Sebastian Brunemeier (former Principal at Apollo Health Ventures, co-founder of Ca
PE Weekly: Healthcare Tech, Services Come Back Into Focus | ACG Insights (Formerly Middle Market Growth) About Advertise Subscribe // ACG About Advertise Subscribe // ACG Magazines The Latest Multimedia Podcast Video Sectors Manufacturing and Industrials Technology Healthcare Consumer Products Food and Agriculture Business and Financial Services Next Target Deal Stage Business Development Due Diligence Deal Execution Value Creation Exit People 2026 BD Pros to Watch Home News & Trends Latest News PE Weekly: Healthcare Tech, Services Come Back Into Focus PE Weekly: Healthcare Tech, Services … l acquire the company. Fundraising 26North Raises $5.9 Billion for Inaugural PE Fund. 26North Partners announced the close of its inaugural private equity fund with $5.9 billion in capital commitments, surpassing its initial $4 billion target. The fund will focus on investments in middle- and upper-middle-market companies, and has already completed seven equity investments. Topspin Raises $328 Million for Consumer Investments. Topspin Consumer Partners, a private equity firm … umer Partners, a private equity firm focused on the consumer sector, closed its Fund III with $328 million in capital commitments. The firm said Fund III will continue to focus on investing in health and wellness, personal care, beauty, food and beverage, household goods, and pet, among other consumer-focused verticals. Middle Market Growth is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.ac
Healthcare Private Placement and M&A Transactions Review Week Ending July 21, 2024 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending July … led by Canaan Partners and Bioqube Ventures on July 16, 2024. Novartis Venture Fund, Jeito, Brandon Capital, Omega Funds, Gilde Healthcare, Forbion and Vesalius Biocapital Partners also participated in the round. The company is an operator of a biopharmaceutical business intended to develop antibodies in patients to improve cancer treatment options. Scorpion Therapeutics: The company raised $150 million in Series C venture funding in a deal led by Frazier Healthcare Partners … Spark Growth Ventures, Warren Point Capital, Frederic H. Moll, Angel Physicians Fund, Band of Angels, Keiretsu Forum and Som Tech also participated in the round. The company is a developer of a portable magnetic resonance imaging (MRI) system designed to diagnose prostate cancer disease. Adona Medical: The company raised $33.5 million of Series C venture funding in a deal led by Cormorant Asset Management and The Capital Partnership on July 10, 2024, putting the company’ … utting the company’s pre-money valuation at $131.5 million. PA MedTech VC Fund, Unorthodox Ventures, Excelestar Ventures, AMED Ventures and other undisclosed investors also participated in the round. The company is a pre-clinical stage medical technology company developing next-generation interatrial shunting and remote patient monitoring solutions for patients with advanced heart failure. miRecule: The company raised $30 million of venture funding from Sanofi on July 1 … itals, TELUS Global Ventures and Andreessen Horowitz on July 18, 2024. Founders Fund and Khosla Ventures also participated in the round. The company is an operator of a clinical digital twin platform designed to assess the medical history of patients in order to flag their immediate and future health risks. 858 Therapeutics: The company raised $2
ONCOtherapeutics You are using an outdated browser. Please upgrade your browser to improve your experience. --> Active Clinical Trials Our Team Solutions Industry & CROs Sites & Investigators Patients & Caregivers Therapeutics Insights About Our Team Resources Active Clinical Studies Press Releases Contact Solutions Industry & CROs Sites & Investigators Patients & Caregivers Therapeutics Insights About Our Team Resources Active Clinical Studies Press Releases Contact Committed To Extending the Lives of Patients-- We are a strategic Contract Research Organization (
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Communications Press Releases … the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards. Click here to submit! Adcendo secures $75M to advance ADC pipeline Adcendo closed an oversubscribed $75 million Series C financing round to support the continued development of its antibody-drug conjugate (ADC) portfolio targeting cancers with high unmet need. 1The round was led by Jeito Capital, alongside a mix of new and existing investors, underscoring sustained confidence in the ADC space. Proceeds are expe
Our Team — Oncolife Therapeutics Oncolife Therapeutics Home Cancer Our Team Media/Investors Home Cancer Our Team Media/Investors Oncolife Therapeutics our team Guy Barry, Ph.D Director, CEO Guy is a director and co-founder at OncoLife Therapeutics. He was instrumental in conceiving and creating the bioinformatic platform that underlies target discovery and the ageing projects. Guy brings extensive experience to OncoLife both in laboratory science and biotechnology. He comes from running his own laboratory of Neurogenomics at QIMR Berghofer in Brisbane where he focussed on m
#034: June 9th, 2021 - Longevity Marketcap Telemetry Longevity Marketcap Newsletter Subscribe Sign in #034: June 9th, 2021 - Longevity Marketcap Telemetry Aducanumab! VitaDAO token sale. Lineage Cell. Non-Traditional. Nathan S. Cheng Jun 10, 2021 1 Share Announcements Last Week in Longevity Longevity Futures Capital Raise Radar Longevity Jobs New Companies on Longevity List Non-Traditional My Links * Disclaimer : None of this should be taken as financial advice. It is for educational purposes only. Mission: To grow a wave of passionate people building, funding, and championing technologies tha … ucanumab gets FDA approval. On Monday, the FDA made a controversial decision to grant accelerated approval to Biogen ’s aducanumab antibody therapy to treat Alzheimer’s disease. The approval is conditional on the requirement of Phase 4 trials that confirm aducanumab’s efficacy within nine years, or the approval could be rescinded by the FDA. This marks the first new drug approved for Alzheimer’s disease in 20 years. The approval was surprising. An independent expert committee … - June 23rd . VitaDAO is a decentralized autonomous organization that seeks to fund longevity research and commercialize the resulting intellectual property -- all on the Ethereum blockchain. The VitaDAO tokens generated in the “genesis” event starting June 18th give holders voting rights for research proposals, commercialization, and the operation of the DAO. Those that would like to participate in the token sale will need a non-exchange crypto wallet, such as Metamask , ho … warded a Ph.D. from Cambridge. Laura Deming Affiliation: Founder, The Longevity Fund Background: Physics, Cynthia Kenyon’s Lab. In 2011, Laura Deming, a Thiel Fellow and former protege of Cynthia Kenyon, founded the first longevity-focussed venture fund at the age of 17. Although she did some C. elegans biology work in Kenyon’s lab when she was 14, she actually went on to study physics at MIT. Laura Deming would later drop out after being awarded a Thiel Fellowship. The rest … on Twitch, has a fondness for bionumbers, first principles thinking, etc). Her fund, The Longevity Fund, invests in companies that sometimes have an unusual aging angle. Matt Scholz Affiliation: Oisin Biotechnologies, OncoSenX, Immusoft Background: Computer science, physics Matt Scholz started his career in computer science and computer security
Health & PHARMA's ONCOLife: The Future of Oncolytic Viruses and Their Role in Cancer Treatment | Oncolytics Biotech Inc. Skip to content About Us Our Mission Leadership Board of Directors Careers Contact Our Science Overview Resources Expanded Access Pipeline Investors Overview News Events Stock Information Filings Corporate Governance FAQs About Us Our Mission Leadership Board of Directors Careers Contact Our Science Overview Resources Expanded Access Pipeline Investors Overview News Events Stock Information Filings Corporate Governance FAQs About Us Our Mission Leadership Board of D
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up You must have cookies enabled to login Refresh (When Cookies Enabled) Forgotten your password? By continuing, yo … s of Service , Privacy Policy and Cookie Policy . View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgrade to a Paid P … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Create a Free Account to Follow Companies To continue, pleas
Portfolio | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Our Portfolio IPO / Acquired Investments Biotherapeutic Digital Health All abcuro Close Private Newton, MA www.abcuro.com Developing treatments for autoimmune and cancer indications. Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 … ence. Press releases Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Jan 10, 2022 Read More Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform. Mar 25, 2021 Read More Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health Jul 01, 2020 Read More Evidation Health and BARDA Partner on Early Warning System for COVID-19 Jun 04, 2020 Read More Evidation … erited Metabolic Disorders Jul 29, 2014 Read More Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders Jun 30, 2014 Read More Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium Jun 05, 2014 Read More Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients … eutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund Apr 09, 2020 Read More Icosavax Close Acquired Seattle www.icosavax.com Focusing on developing safe and effective vaccines against infectious diseases. Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like parti … res $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support. Feb 25, 2021 Read More Minervax Close Private Copenhagen, Denmark minervax.com Developing a prophylactic vaccine against Group B Streptococcus. Minervax is a clinical stage biotechnology company developing a prophylactic
Altogen Labs - Altogen Labs offers the HCC827 xenograft... Facebook Log In Altogen Labs's Post Altogen Labs May 15, 2025 · Shared with Public Altogen Labs offers the HCC827 xenograft model as part of portfolio of in-house validated cancer models. The HCC827 cell line, derived from human non-small cell lung adenocarcinoma, harbors a well-characterized activating deletion in exon 19 of the EGFR gene (E746-A750del), rendering it highly responsive to EGFR-targeted therapies. When implanted subcutaneously into immunodeficient mice, such as athymic nude or NOD/SCID strains, HCC827 cells produce
Cancer — Oncolife Therapeutics Oncolife Therapeutics Home Cancer Our Team Media/Investors Home Cancer Our Team Media/Investors Oncolife Therapeutics cancer Unique bioinformatic platform uncovers cancer-specific genes We at OncoLife believe that effective cancer therapies need not be harmful to the patient. The recent advent of next generation data has permitted unprecedented insight into the specific genes driving cancer cell growth. This provides the exciting possibility of discovering therapeutic targets that are unique to the progression of each cancer type, but critical
#028: April 19th, 2021 - Longevity Marketcap Telemetry Longevity Marketcap Newsletter Subscribe Sign in #028: April 19th, 2021 - Longevity Marketcap Telemetry Samumed shakeup and IPO. LongevityBase.org. 12 Seconds to Mars. Nathan S. Cheng Apr 20, 2021 1 Share Announcements Capital Raise Radar Last Week in Longevity Longevity Futures Longevity Jobs New Companies on Longevity List 12 Seconds to Mars My Links * Disclaimer : None of this should be taken as financial advice. It is for educational purposes only. Mission: To grow a wave of passionate people building, funding, and championing technolo … oing to be posting a task on 1729.com to incentivize volunteers to get the ball rolling on an open-source database for things that modulate biological aging. Basically, I want people to read longevity intervention research papers (in mammalian models and humans) and add entries to the LongevityBase Airtable. One parameter of aging (lifespan or some phenotype of aging) per line. The goal is to get to a critical database mass at which point people will volunteer to maintain it. … investors only. $50K minimum check size. Other investors include The Methuselah Fund , Kizoo Technology Capital . Ponce de Leon Health // Raising $15M // Article : Makers of Rejuvant Life Tabs , a calcium alpha-ketoglutarate supplement (CaAKG). Alpha-ketoglutarate is a key molecule in the Krebs cycle. Brian Kennedy (former head of Buck Institute, now at the National University of Singapore) is the CSO of this company. CaAKG supplementation reduces frailty and extends maximum … c clock, GrimAge , has been reported to predict mortality and healthspan so the application for life insurance is natural. If they prove successful these clocks could eventually be used systematically in health and wellness, or perhaps as an FDA-approved surrogate biomarker for aging. Treefrog Therapeutics announces 15 billion human iPSCs produced in a single 10L bioreactor in one week. Treefrog Therapeutics is a stem cell company based in France that is developing regenerati … age-related diseases and slowing aging. This is a more than worthy consolation prize should we fail to reverse aging in our lifetimes. And if we fail, those in the future will carry on in our place until victory is assured. The quanta of progress I don’t know how long it might take to develop technologies that cure aging. But what I do know for
Cancer — Oncolife Therapeutics Oncolife Therapeutics Home Cancer Our Team Media/Investors Home Cancer Our Team Media/Investors Oncolife Therapeutics cancer Unique bioinformatic platform uncovers cancer-specific genes We at OncoLife believe that effective cancer therapies need not be harmful to the patient. The recent advent of next generation data has permitted unprecedented insight into the specific genes driving cancer cell growth. This provides the exciting possibility of discovering therapeutic targets that are unique to the progression of each cancer type, but critical
Company Archive - Page 495 Company Archive - Page 495 OLYMPUS TILING CO. PTY. LTD. OLYMPUS TOWNS PTY. LTD. OLYMPUS TUTORING PTY LTD OLYMPUS WAY PTY. LTD. OLYMPUS WEALTH MANAGEMENT PTY LTD OLYMPUS WINDOWS AND DOORS PTY LTD OLYNDA PTY LTD OLYNIA PTY LTD OLYNIK RETIREMENT PROPERTY HOLDING COMPANY NO. 1 PTY LTD OLYNIK RETIREMENT PTY. LTD. O LYNN ENTERPRISE PTY LTD O LYNN PTY. LTD. OLYNSELL NOMINEES PTY. LTD. OLYNTHOS AUSTRALIA PTY LTD OLYNTHOS BRIDGETOWN PTY LTD OLYNTHOS GROUP PTY LTD OLY PTY LTD OLYRED (NSW) PTY LTD OLY & REID PTY LTD OLYRE PTY LTD OLYSCAR PTY LTD OLYSIA PTY LTD OLYSSA PTY LT … TY LIMITED O'MALLEY SUPERANNUATION INVESTMENTS PTY LTD O'MALLEY SUPER FUND PTY LTD O'MALLEY SUPER INVESTMENTS PTY LTD O'MALLEY SUPER PTY LTD O'MALLEY TRANSPORT PTY LTD O'MALLEY & YOUNG INVESTMENTS PTY LTD OMALLY CONSULTING PTY LTD O'MALLY-HINE PTY LTD OMA LOGISTICS PTY LTD OMALOS PTY LTD OMAL PTY LTD OMA MANAGEMENT PTY LTD OMAMANLY PTY LTD OMAMA PTY LTD OMA MCTAVISH PTY LTD O'MAMI PTY LTD. OMAM PTY LTD OMANA AGRI PTY LTD OMANA ENTER … IMITED OMAR DENTAL PTY LTD OMAR DEVELOPMENTS PTY LTD OMARD PTY LTD OMAR D SUPER FUND PTY LTD OMAREE PTY LTD OMARE PTY LTD OMARETA PTY LTD OMAR FAMILY COMPANY PTY. LTD. OMAR FAMILY FINANCE HOLDINGS PTY LTD OMAR & FAMILY HOLDINGS PTY LTD OMAR FAMILY PTY LTD OMAR FINANCE PTY LTD OMAR GHONIM PTY LTD OMARGOSH PTY LTD OMAR GROUP PTY LTD OMAR HAYAT NOMINEES PTY LTD OMAR HAYAT PROPERTY PTY LTD OMAR HOLDINGS NO. 2 PTY LTD OMAR HOLDINGS PTY LTD OMAR HOLDINGS WA PTY LTD OMAR & H … ES PTY LTD OMARJEE PTY. LIMITED OMARJEE SERVICES PTY LTD OMARJEE SUPERANNUATION FUND PTY LTD OMAR JEWHAR PTY LTD OMAR KAISAR MEDICAL PTY LTD OMARK HOLDINGS PTY LIMITED OMARLIN PTY LTD OMAR MANAGEMENT SERVICES PTY LTD OMAR MASRI AND ASSOCIATES PTY LTD OMAR MEDICAL GROUP PTY LTD OMAR MEMORIAL PTY LTD OMAR MORSI SUPER FUND PTY LTD OMARNY FAMILY PTY LTD OMAROBAID PTY LTD OMAROD HOLDINGS PTY. LTD. OMAROO AUSTRALIA PTY LTD OMAROO FARM PTY LTD OMAROO GROUP PTY LTD OMAROO HOLDINGS PT … OMAR SAID PTY. LTD. OMAR'S EXCAVATION & CONCRETING PTY LTD OMAR'S FUND PTY LTD OMAR SHAHID PTY LTD OMAR SHARIF AND CO PTY LTD OMAR SMSF PTY LTD OMAR SOLUTIONS PTY LTD OMAR & SONS PTY LTD OMARS PAINTING & DECORATING PTY LTD OMARS PAINTING SERVICES PTY LTD OMAR & TASRINA PROPERTY PTY LTD OMAR & TASRINA SUPERANNUATION P
Oncolife Therapeutics Oncolife Therapeutics Home Cancer Our Team Media/Investors Home Cancer Our Team Media/Investors Oncolife Therapeutics Scroll We at oncoLife Therapeutics foresee a future where cancer therapies will no longer be harmful to the patient Our Mission Understanding human stem cell biology will uncover molecular therapies that will safely and effectively treat cancer Our passion comes from our curiosity and our drive to pioneer ideas that will transform the world. We believe that a greater understanding of cell biology will advance me
Altogen Labs - Colorectal cancer remains a major global... Facebook Log In Altogen Labs's Post Altogen Labs June 20, 2025 · Shared with Public Colorectal cancer remains a major global health concern, with high rates of morbidity and mortality, particularly in patients with advanced or treatment-resistant disease. Progress in developing more effective therapies depends on reliable preclinical models that closely replicate the molecular complexity of human tumors. The DLD-1 xenograft model is an essential tool in colorectal cancer research, enabling in vivo evaluation of therapeutic efficac
oncoLife Therapeutics — investment search application on «startup.network» 52654 oncoLife Therapeutics Anti-ageing through stem cells and metabolism Australia Market: Medicine Stage of the project: Idea or something is already done Date of last change: 13.06.2021 Startup.Network Startups and Investment Projects oncoLife Therapeutics Go to the owner's profile 7 equalizer from 2000 help Calculated and estimated occupancy of the project (more about ratings) My rating 1 2 3 4 5 6 7 8 9 10 Average rating: Idea We have three main focus areas: (1) A unique cancer drug discov
Top "stem cell biology" companies | VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of … m/ Create a Free Account to access Downloads View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
Oncolife Therapeutics Oncolife Therapeutics Home Cancer Our Team Media/Investors Home Cancer Our Team Media/Investors Oncolife Therapeutics Scroll We at oncoLife Therapeutics foresee a future where cancer therapies will no longer be harmful to the patient Our Mission Understanding human stem cell biology will uncover molecular therapies that will safely and effectively treat cancer Our passion comes from our curiosity and our drive to pioneer ideas that will transform the world. We believe that a greater understanding of cell biology will advance me
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
OncoLife Therapeutics - 2026 Company Profile, Team & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks … der of DNA sequencing for cancer detection $332M Merck Global Health Innovation Fund , DFJ Growth ... & 19 others 68/100 10th Foresight Diagnostics 2020 , Aurora ( United States ) , Acquired Developer of minimally-invasive liquid biopsy test for the detection of cancer $104M Foresite Capital , Civilization Ventures & 6 others 66/100 547th OncoLife Therapeutics 2020 , Brisbane ( Australia ) , Unfunded Developer of in-vivo and in-vitro diagnostic solution for specific o